Nanexa (NANEXA) investor relations material

Executive summary

• Achieved breakthrough preclinical results for monthly and three-month semaglutide depot formulations, demonstrating unique and consistent release profiles.

• Strengthened financial position through Moderna agreement revenue and full exercise of warrants, securing funding through mid-2027.

• Increased industry presence and interest in PharmaShell® technology, with ongoing discussions for new licensing and development partnerships.

• Expanded R&D and production capacity planning to support anticipated growth and partnerships.

Financial highlights

• Q1 2026 turnover was SEK 1,632 thousand, down from SEK 2,877 thousand year-over-year.

• Operating profit (EBIT) was SEK -13,610 thousand, compared to SEK -8,213 thousand in Q1 2025.

• Net loss for the quarter was SEK -14,023 thousand, versus SEK -8,987 thousand last year.

• Earnings per share were SEK -0.08, compared to SEK -0.06 in Q1 2025.

• Cash and cash equivalents at period end were SEK 73,022 thousand, up from SEK 49,216 thousand.

Outlook and guidance

• Current working capital and cash are sufficient to finance operations through Q2 2027.

• Active efforts underway to secure additional revenue from new pharmaceutical agreements.

• Anticipates further strategic partnerships and milestones in diabetes and obesity treatment development.